Regeneron Pharmaceuticals Inc (REGN) Common Stock USD0.001

Sell:$700.29Buy:$701.19$4.31 (0.62%)

NASDAQ:2.20%
Market closed | Prices delayed by at least 15 minutes
Sell:$700.29
Buy:$701.19
Change:$4.31 (0.62%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$700.29
Buy:$701.19
Change:$4.31 (0.62%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Key people

Leonard S. Schleifer
Co-Chairman of the Board, President, Chief Executive Officer, Founder
George D. Yancopoulos
Co-Chairman of the Board, President, Chief Scientific Officer
Christopher R. Fenimore
Chief Financial Officer, Senior Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Marion E. McCourt
Executive Vice President - Commercial
Andrew J. Murphy
Executive Vice President - Research
Neil Stahl
Executive Vice President - Research and Development
Jason Pitofsky
Vice President, Controller
Christine A. Poon
Lead Independent Director
Bonnie L. Bassler
Independent Director
Michael S. Brown
Independent Director
N. Anthony Coles
Independent Director
Joseph L. Goldstein
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US75886F1075
  • Market cap
    $74.96bn
  • Employees
    15,106
  • Shares in issue
    135.71m
  • Exchange
    NASDAQ
  • Index
    S&P 500, NASDAQ 100 Index, TR Equity United States Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.